Heart rate and the cardiometabolic risk

Current Hypertension Reports

Volumn 15, Issue 3, 2013, Pages 253-259

  Palatini, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Autonomic dysfunction; Diabetes; Exercise; Heart rate; Hypertension; Insulin resistance; Metabolic syndrome; Obesity; Sympathetic; Tachycardia

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIURETIC AGENT; NEBIVOLOL;

ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR MORTALITY; DISEASE ASSOCIATION; DRUG EFFECT; FOLLOW UP; HEART HEMODYNAMICS; HEART RATE; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL RATE; SYMPATHETIC TONE;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HEART RATE; HUMANS; METABOLIC SYNDROME X; RISK;

EID: 84877791662     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0342-7     Document Type: Article

References (61)

1. Palatini P. Elevated heart rate in cardiovascular diseases: a target for treatment? Prog Cardiovasc Dis. 2009;52:46-60.
2. Reil JC, Bohm M. The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol. 2007;96:585-92.
3. Palatini P, Benetos A, Grassi G, European Society of Hypertension, et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens. 2006;24:603-10.
4. Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol. 2011;8:369-79.
5. • Palatini P. Role of elevated heart rate in the development of cardiovascular disease in hypertension. Hypertension. 2011;58:745-50. This article summarizes the most recent information on the clinical significance of elevated heart rate in hypertension. In particular, it provides an update of the predictive capacity of heart rate for cardiovascular mortality in the most recent clinical trials in hypertensive patients.
6. Julius S, Valentini M, Palatini P. Overweight and hypertension: a two-way street? Hypertension. 2000;35:807-13.
7. Mancia G, Bousquet P, Elghozi JL, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens. 2007;25:909-20.
8. • Grassi G, Arenare F, Quarti-Trevano F, et al. Heart rate, sympathetic cardiovascular influences, and the metabolic syndrome. Prog Cardiovasc Dis. 2009;52:31-7. This article reviews the evidence for increased sympathetic activity in hypertension and highlights the role of the autonomic nervous system dysfunction as a determinant of metabolic disturbances.
9. Palatini P. Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease. Curr Hypertens Rep. 2001;3 Suppl 1:S3-9.
10. Palatini P, Casiglia E, Pauletto P, et al. Relationship of tachycardia with high blood pressure and metabolic abnormalities. A Study with Mixture Analysis in three Populations. Hypertension. 1997;30:1267-73.
11. Mancia G, Bombelli M, Corrao G, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension. 2007;49:40-7.
12. Gilardini L, Parati G, Sartorio A, et al. Sympathoadrenergic and metabolic factors are involved in ambulatory blood pressure rise in childhood obesity. J Hum Hypertens. 2008;22:75-82.
13. Perlini S, Naditch-Brule L, Farsang C, et al. Pulse pressure and heart rate in patients with metabolic syndrome across Europe: insights from the GOOD survey. J Hum Hypertens. 2012. doi: 10.1038/jhh.2012.61.
14. Charakida M, Jones A, Falaschetti E, et al. Childhood obesity and vascular phenotypes: a population study. J Am Coll Cardiol. 2012;60:2643-50.
15. Yano Y, Haimoto H, Hoshide S, et al. Evening heart rate measured at home is associated with visceral obesity and abnormal fat distribution in patients with hypertension. Am J Hypertens. 2011;24:783-8.
16. Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474-80.
17. Liang J, Li Y, Zhou N, et al. Synergistic effects of serum uric Acid and cardiometabolic risk factors on early stage atherosclerosis: the cardiometabolic risk in chinese study. PLoS One. 2012;7:e51101.
18. Redon J, Cifkova R, Laurent S, Scientific Council of the European Society of Hypertension, et al. The metabolic syndrome in hypertension: European Society of Hypertension position statement. J Hypertens. 2008;26:1891-900.
19. Shigetoh Y, Adachi H, Yamagishi S, et al. Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population. Am J Hypertens. 2009;22:151-5.
20. • Palatini P, Mos L, Santonastaso M, et al. Resting heart rate as a predictor of body weight gain in the early stage of hypertension. Obesity. 2011;19:618-23. This study provides evidence for a longitudinal connection between baseline heart rate and risk of obesity and shows that also heart rate measured during the follow-up may influence body weight gain.
21. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertens. 1997;15:3-17.
22. Palatini P, Vriz O, Nesbitt S, et al. Parental hemodynamic circulation predicts insulin resistance in offspring. The Tecumseh Offspring Study. Hypertension. 1999;33:769-74.
23. Palatini P, Majahalme S, Amerena J, et al. Determinants of left ventricular structure and mass in young subjects with sympathetic over-activity. The Tecumseh Offspring Study. J Hypertens. 2000;18:769-75.
24. Palatini P, Longo D, Zaetta V, et al. Evolution of blood pressure and cholesterol in stage 1 hypertension: role of autonomic nervous system activity. J Hypertens. 2006;24:1375-81.
25. Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol. 2010;141:122-31.
26. Kannel WB, Brand N, Skinner Jr JJ, et al. The relation of adiposity to blood pressure and development of hypertension. Ann Intern Med. 1967;67:48-59.
27. Valentini M, Julius S, Palatini P, et al. Attenuation of hemodynamic metabolic and energy expenditure responses to isoproterenol in patients with hypertension. J Hypertens. 2004;22:1999-2006.
28. Stettler C, Bearth A, Allemann S, et al. QTc interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up. Diabetologia. 2007;50:186-94.
29. Linnemann B, Janka HU. Prolonged QTc interval and elevated heart rate identify the type 2 diabetic patient at high risk for cardiovascular death. The Bremen Diabetes Study. Exp Clin Endocrinol Diabetes. 2003;111:215-22.
30. Cardoso CR, Salles GF, Deccache W. Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study. J Diabetes Complications. 2003;17:169-78.
31. Anselmino M, Ohrvik J, Ryden L. Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J. 2010;31:3040-5.
32. Carnethon MR, Yan L, Greenland P, Garside DB, Dyer AR, Metzger B, et al. Resting heart rate in middle age and diabetes development in older age. Diabetes Care. 2008;31:335-9.
33. • Hillis GS, Woodward M, Rodgers A, et al. Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus. Diabetologia. 2012;55:1283-90. This is the most recent prospective study on the predictive capacity of heart rate for mortality in a diabetic sample. In this large population from the ADVANCE study, heart rate showed a strong association with future all-cause mortality, cardiovascular death and major cardiovascular outcomes.
34. Hillis GS, Hata J, Woodward M, et al. Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus. J Am Heart Assoc. 2012;1:e002832.
35. Barthel P, Bauer A, Müller A. Reflex and tonic autonomic markers for risk stratification in patients with type 2 diabetes surviving acute myocardial infarction. Diabetes Care. 2011;34:1833-7.
36. Palatini P, Dorigatti F, Zaetta V, et al. Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens. 2006;24:1873-80.
37. Jouven X, Empana JP, Escolano S, et al. Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged men. Am J Cardiol. 2009;103:279-83.
38. Paul L, Hastie CE, Li WS, et al. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension. 2010;55:567-74.
39. Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternal VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J. 2008;29:1327-34.
40. Poulter NR, Dobson JE, Sever PS, et al. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol. 2009;54:1154-61.
41. Poulter NR, Dobson JE, Sever PS, et al. Elevated heart rate in hypertension: a target for treatment ? Reply. J Am Coll Cardiol. 2010;55:931-2.
42. Okin PM, Kjeldsen SE, Julius S, et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J. 2010;31:2271-9.
43. • Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109:685-92. In this clinical trial performed in a large sample of high-risk hypertensive patients, antihypertensive treatment proved to be effective in subjects with normal heart rate after one year of treatment, but had little effect on the patients with high in-trial heart rate.
44. Palatini P. Recommendations on how to measure resting heart rate. Medicographia. 2009;31:414-9.
45. Mancia G, Parati G, Pomidossi G, et al. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension. 1987;9:209-15.
46. Palatini P, Winnicki M, Santonastaso M, et al. Reproducibility of heart rate measured in the clinic and with 24-hour intermittent recorders. Am J Hypertens. 2000;13:92-8.
47. Hozawa A, Ohkubo T, Kikuya M, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens. 2004;17:1005-10.
48. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005;111:1777-83.
49. Hansen TW, Thijs L, Boggia J, et al. Prognostic value of ambulatory heart rate revisited in 6928 subjects from 6 populations. Hypertension. 2008;52:229-35.
50. Hozawa A, Inoue R, Ohkubo T, et al. Predictive value of ambulatory heart rate in the Japanese general population: the Ohasama study. J Hypertens. 2008;26:1571-6.
51. Palatini P, Thijs L, Staessen JA, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med. 2002;162:2313-21.
52. Ben-Dov IZ, Kark JD, Ben-Ishay D, et al. Blunted heart rate dip during sleep and all-cause mortality. Arch Intern Med. 2007;167:2116-21.
53. • Palatini P, Reboldi G, Beilin LJ, et al. Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. Int J Cardiol 2013. doi: 10.1016/j.ijcard.2012.12.103. This is the most recent study on the predictive capacity of ambulatory heart rate for cardiovascular events. It highlights the better predictive power of heart rate recorded during sleep compared to heart rate measured during waking hours.
54. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875-85.
55. James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905-17.
56. Palatini P. Cardiovascular effects of exercise in young hypertensives. Int J Sports Med. 2012;33:683-90.
57. Blohm D, Ploch T, Apelt S. Efficacy of exercise therapy to reduce cardiometabolic risk factors in overweight and obese children and adolescents: a systematic review. Dtsch Med Wochenschr. 2012;137:2631-6.
58. Palatini P, Visentin P, Dorigatti F, et al. Regular physical activity prevents development of left ventricular hypertrophy in hypertension. Eur Heart J. 2009;30:225-32.
59. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227-36.
60. Grassi G, Trevano FQ, Facchini A, et al. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial. Blood Press. 2003;2:35-40.
61. Grassi G. Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens. 2004;13:513-9.